Page 2 - Pharma Industry

Mankind Pharma Q2 PAT drops 21% on high finance costs; revenue up 20%

Mankind Pharma's Q2 FY26 profit fell to Rs 520 crore on higher finance and input costs, even as strong domestic and export growth lifted revenue by over 20%.

NPPA fixes retail price of 28 drugs, ceiling price of six formulations

The National Pharmaceutical Pricing Authority has revised retail prices of 28 formulations and capped ceiling prices for six drugs under the National List of Essential Medicines

Lupin Q2 PAT rises 73% on strong growth across key global markets

Lupin's consolidated profit rose 73% YoY to Rs 1,478 crore in Q2 FY26, led by robust sales in India and the US and higher margins from an improved product mix

Alembic Pharma Q2 profit rises 21% on robust US generics and API growth

Alembic Pharma's consolidated profit rose 21% to Rs 185 crore in Q2 FY26, led by strong performance in US generics, APIs, and international markets, with six new ANDA approvals

Gland Pharma Q2 results: Profit rises 12% on recovery at Europe's Cenexi

The consolidated net profit rose to 1.84 billion rupees (nearly $21 million) for the quarter ended September 30 from 1.64 billion rupees a year earlier

Achin Gupta to succeed Umang Vohra as Cipla MD & GCEO from April 2026

Umang Vohra joined Cipla in 2015 as global chief financial and strategy officer and thereafter served as the company's MD & GCEO since 2016

Centre brings draft rules to debar drugmakers who provide fake information

The health ministry proposes new provisions under the Drugs Rules, 1945, allowing regulators to bar applicants who submit fake or misleading data for approvals

Cough syrup deaths: CDSCO launches digital tracker for high-risk solvents

The regulator's ONDLS-based monitoring platform will track supply chains and quality of solvents used in drug manufacturing following child deaths linked to toxic cough syrups

Biocon Biologics gets Health Canada approval for Yesintek, Yesintek I.V.

The approval of Yesintek and Yesintek I.V., biosimilars to Stelara, strengthens Biocon Biologics' presence in North America and expands its immunology portfolio

Lilly and Cipla to market tirzepatide in India under new brand Yurpeak

The Lilly-Cipla collaboration brings a second brand of tirzepatide, Yurpeak, to India, aiming to widen patient access for diabetes and obesity care across urban and semi-urban markets

Results preview: Pharma sales may be up 9-10% in Q2 on robust domestic biz

Domestic business and exports are expected to be a shot in the arm; hospitals and diagnostics to lag

Risdiplam generic drug case: SC rejects Roche plea against Natco pharma

The Supreme Court upheld Delhi HC's interim order allowing Natco Pharma to manufacture and sell a generic version of Roche's spinal muscular atrophy drug Risdiplam

Centre refuses deadline extension for pharma firms after Coldrif deaths

The decision to turn down requests from drug manufacturers for more time came after it was highlighted that Sresan Pharmaceutical, the company that produced Coldrif, did not upgrade its facilities

India's pharma regulatory failures point to a deeper structural flaw

These are not independent, random occurrences. They are all pointers to a larger, more fundamental issue

Datanomics: Surge in substandard drugs raises safety concerns in India

India faced global scrutiny in 2023 when its cough syrups were linked to the deaths of dozens of children in Gambia

Indian pharma market grows 7.3% in September, chronic drugs gain traction

India's pharmaceutical market rose 7.3% year-on-year in September to ₹20,886 crore, driven by robust growth in antidiabetic, cardiac, and respiratory therapies

Equity investors shift focus from export sectors amid US trade hurdles

Weighting of domestic demand-driven sectors surges; 'sunrise' stocks leap ahead

Madhya Pradesh, Rajasthan probe child deaths linked to cough syrup

Drug authorities in Madhya Pradesh and Rajasthan are probing child deaths linked to cough syrup supplied to government hospitals, with testing of samples and quality concerns

GSK Pharma gains depend on new launches, traction in base business

The Q1 was impacted by sluggish show of the base business and supply disruption, resulting in brokerages cutting their earnings estimates

Datanomics: India doubles its share in prescription drugs to the US

The Indian pharma stocks tanked after the announcement due to the ambiguity surrounding the impact of tariff on complex generics and specialty medicines supplied by the Indian pharma companies